These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 31379857)

  • 1. Increased NK Cell Count in Multiple Sclerosis Patients Treated With Dimethyl Fumarate: A 2-Year Longitudinal Study.
    Marastoni D; Buriani A; Pisani AI; Crescenzo F; Zuco C; Fortinguerra S; Sorrenti V; Marenda B; Romualdi C; Magliozzi R; Monaco S; Calabrese M
    Front Immunol; 2019; 10():1666. PubMed ID: 31379857
    [No Abstract]   [Full Text] [Related]  

  • 2. Treatment response to dimethyl fumarate is characterized by disproportionate CD8+ T cell reduction in MS.
    Fleischer V; Friedrich M; Rezk A; Bühler U; Witsch E; Uphaus T; Bittner S; Groppa S; Tackenberg B; Bar-Or A; Zipp F; Luessi F
    Mult Scler; 2018 Apr; 24(5):632-641. PubMed ID: 28436295
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dimethyl fumarate induces changes in B- and T-lymphocyte function independent of the effects on absolute lymphocyte count.
    Longbrake EE; Cantoni C; Chahin S; Cignarella F; Cross AH; Piccio L
    Mult Scler; 2018 May; 24(6):728-738. PubMed ID: 28480794
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dimethyl fumarate selectively reduces memory T cells in multiple sclerosis patients.
    Longbrake EE; Ramsbottom MJ; Cantoni C; Ghezzi L; Cross AH; Piccio L
    Mult Scler; 2016 Jul; 22(8):1061-1070. PubMed ID: 26459150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relapsing-Remitting Multiple Sclerosis Is Characterized by a T Follicular Cell Pro-Inflammatory Shift, Reverted by Dimethyl Fumarate Treatment.
    Cunill V; Massot M; Clemente A; Calles C; Andreu V; Núñez V; López-Gómez A; Díaz RM; Jiménez MLR; Pons J; Vives-Bauzà C; Ferrer JM
    Front Immunol; 2018; 9():1097. PubMed ID: 29896193
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of dimethyl fumarate on lymphocytes in RRMS: Implications for clinical practice.
    Mehta D; Miller C; Arnold DL; Bame E; Bar-Or A; Gold R; Hanna J; Kappos L; Liu S; Matta A; Phillips JT; Robertson D; von Hehn CA; Campbell J; Spach K; Yang L; Fox RJ
    Neurology; 2019 Apr; 92(15):e1724-e1738. PubMed ID: 30918100
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fingolimod and Dimethyl-Fumarate-Derived Lymphopenia is not Associated with Short-Term Treatment Response and Risk of Infections in a Real-Life MS Population.
    Boffa G; Bruschi N; Cellerino M; Lapucci C; Novi G; Sbragia E; Capello E; Uccelli A; Inglese M
    CNS Drugs; 2020 Apr; 34(4):425-432. PubMed ID: 32193826
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of hematological abnormalities in multiple sclerosis patients treated with fingolimod and dimethyl fumarate and impact of treatment switch on lymphocyte and leukocyte count.
    Baharnoori M; Gonzalez CT; Chua A; Diaz-Cruz C; Healy BC; Stankiewicz J; Weiner HL; Chitnis T
    Mult Scler Relat Disord; 2018 Feb; 20():51-57. PubMed ID: 29304497
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dimethyl Fumarate Selectively Reduces Memory T Cells and Shifts the Balance between Th1/Th17 and Th2 in Multiple Sclerosis Patients.
    Wu Q; Wang Q; Mao G; Dowling CA; Lundy SK; Mao-Draayer Y
    J Immunol; 2017 Apr; 198(8):3069-3080. PubMed ID: 28258191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of dimethyl fumarate on lymphocyte subsets.
    Berkovich R; Weiner LP
    Mult Scler Relat Disord; 2015 Jul; 4(4):339-41. PubMed ID: 26195053
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dimethyl fumarate induces a persistent change in the composition of the innate and adaptive immune system in multiple sclerosis patients.
    Montes Diaz G; Fraussen J; Van Wijmeersch B; Hupperts R; Somers V
    Sci Rep; 2018 May; 8(1):8194. PubMed ID: 29844361
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High CD4+:CD8+ ratios with herpes zoster infections in patients with multiple sclerosis on dimethyl fumarate.
    Balshi A; Saart E; Pandeya S; Dempsey J; Baber U; Sloane JA
    Mult Scler; 2023 Oct; 29(11-12):1465-1470. PubMed ID: 37572049
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dimethyl fumarate-related immune and transcriptional signature is associated with clinical response in multiple sclerosis-treated patients.
    Sánchez-Sanz A; García-Martín S; Sabín-Muñoz J; Moreno-Torres I; Elvira V; Al-Shahrour F; García-Grande A; Ramil E; Rodríguez-De la Fuente O; Brea-Álvarez B; García-Hernández R; García-Merino A; Sánchez-López AJ
    Front Immunol; 2023; 14():1209923. PubMed ID: 37483622
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Repopulation of T, B, and NK cells following alemtuzumab treatment in relapsing-remitting multiple sclerosis.
    Gilmore W; Lund BT; Li P; Levy AM; Kelland EE; Akbari O; Groshen S; Cen SY; Pelletier D; Weiner LP; Javed A; Dunn JE; Traboulsee AL
    J Neuroinflammation; 2020 Jun; 17(1):189. PubMed ID: 32539719
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Delayed lymphocyte re-population following discontinuation of dimethyl fumarate and after switching to other disease modifying drug therapies.
    Khatri BO; Tarima SS; Essig B; Sesing J; Olapo T
    Mult Scler Relat Disord; 2017 Nov; 18():60-64. PubMed ID: 29141823
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dimethyl fumarate treatment alters NK cell function in multiple sclerosis.
    Smith MD; Calabresi PA; Bhargava P
    Eur J Immunol; 2018 Feb; 48(2):380-383. PubMed ID: 29108094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors associated with dimethyl fumarate-induced lymphopenia.
    Sainz de la Maza S; Medina S; Villarrubia N; Costa-Frossard L; Monreal E; Tejeda-Velarde A; Rodríguez-Martín E; Roldán E; Álvarez-Cermeño JC; Villar LM
    J Neurol Sci; 2019 Mar; 398():4-8. PubMed ID: 30658226
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dimethyl fumarate-induced lymphocyte count drop is related to clinical effectiveness in relapsing-remitting multiple sclerosis.
    Tsantes E; Curti E; Ferraro D; Lugaresi A; Baldi E; Montepietra S; Immovilli P; Simone AM; Mancinelli L; Strumia S; Vitetta F; Foschi M; Ferri C; Ferrarini C; Sola P; Granella F
    Eur J Neurol; 2021 Jan; 28(1):269-277. PubMed ID: 32931130
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cross-sectional analysis of peripheral blood mononuclear cells in lymphopenic and non-lymphopenic relapsing-remitting multiple sclerosis patients treated with dimethyl fumarate.
    Lee CH; Jiang B; Nakhaei-Nejad M; Barilla D; Blevins G; Giuliani F
    Mult Scler Relat Disord; 2021 Jul; 52():103003. PubMed ID: 34118574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased multiple sclerosis disease activity in patients transitioned from fingolimod to dimethyl fumarate: a case series.
    Delgado S; Hernandez J; Tornes L; Rammohan K
    BMC Neurol; 2021 Feb; 21(1):48. PubMed ID: 33530945
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.